However, this notion was challenged by the identification of cancer patients harboring a missense mutation that changes a glycine residue in the catalytic signature motif to a glutamate, which was predicted to abolish the lipid phosphatase activity of PTEN while leaving the protein phosphatase activity intact (Liaw et al., 1997; Myers et al., 1997). The gene discussed is PTEN; the disease is cancer.